Prinses Máxima Center for Pediatric Oncology Implements Callisto from Volta Labs to Streamline Clinical Genomics Workflows

The Prinses Máxima Center for Pediatric Oncology has acquired the Callisto platform from Volta Labs to streamline sample preparation across multiple genomics workflows. The platform automates extraction, library preparation, and target enrichment, increasing efficiency and reproducibility while reducing hands-on time for laboratory staff. The implementation will support both Illumina and Oxford Nanopore Technologies sequencing platforms.

BOSTON, Sept. 10, 2025 /PRNewswire/ -- The Prinses Máxima Center for Pediatric Oncology, the largest pediatric cancer center in Europe, has acquired the Callisto™ platform from Volta Labs to streamline sample preparation across multiple genomics workflows. This acquisition supports both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms, aiming to enhance efficiency and reproducibility while reducing hands-on time for laboratory staff.

The Prinses Máxima Center, located in Utrecht, The Netherlands, is dedicated to integrating care and research to improve outcomes for children with cancer. By adopting Callisto, the Center will advance sample preparation across multiple genomics workflows. According to Bastiaan Tops, Head of Laboratory for Childhood Cancer Pathology at the Center, "Callisto's full walk-away automation for multiple sequencing approaches will allow us to establish Illumina whole-genome sequencing as a standard of care for all pediatric patients, while at the same time supporting the adoption of Oxford Nanopore sequencing for rapid diagnosis." The platform automates extraction, library preparation, and target enrichment in a compact, user-friendly system, enabling clinical and research labs to streamline multiple sequencing applications across different platforms without requiring specialized technical expertise.

Volta Labs, a genomics applications company, developed the Callisto platform to maximize the performance and scalability of sample preparation in genomics while providing unparalleled consistency. The adoption of Callisto underscores the growing global demand for automation solutions that improve Next-Generation Sequencing (NGS) efficiency, accuracy, and scalability.

The partnership between the Prinses Máxima Center and Volta Labs highlights the increasing focus on advanced genomic technologies as a standard of care in pediatric oncology. The Center's strong emphasis on innovation, collaboration, and excellence aligns with Volta Labs' mission to bring insights to patients faster through advanced genomic technologies.

About Prinses Máxima Center for Pediatric Oncology
The Prinses Máxima Center for Pediatric Oncology, located in Utrecht, The Netherlands, brings together the best possible care and scientific research for children with cancer. With a strong focus on innovation, collaboration, and excellence, the center aims to cure every child with cancer, with optimal quality of life.

About Volta Labs
Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize the performance and scalability of sample preparation in genomics while providing unparalleled consistency. For more information about our products and services, please visit www.voltalabs.com.

Media Contact
Nicole Ellis Ovadia
Director of Strategic Marketing
Volta Labs, Seaport, MA
Logo - https://mma.prnewswire.com/media/2611556/VoVolta_Labs_Logo.jpg